Approaches to identifying appropriate medication adherence assessments for HIV infected individuals with comorbid bipolar disorder

AIDS Patient Care and STDs

Volumn 26, Issue 7, 2012, Pages 388-394

  Badiee, Jayraan ^a   Riggs, Patricia K ^a   Rooney, Alexandra S ^a   Vaida, Florin ^b   Grant, Igor ^a   Atkinson, J Hampton ^a   Moore, David J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AIDS CLINICAL TRIALS GROUP ADHERENCE QUESTIONNAIRE; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DRUG MONITORING; EDUCATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION EVENT MONITORING SYSTEM; PATIENT ASSESSMENT; PATIENT COMPLIANCE; QUESTIONNAIRE; SELF REPORT; VISUAL ANALOG SCALE;

ADULT; ANTI-HIV AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CALIFORNIA; COMORBIDITY; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV SEROPOSITIVITY; HUMANS; MALE; MEDICATION ADHERENCE; PAIN MEASUREMENT; RISK FACTORS; SELF REPORT;

EID: 84864689990     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0447     Document Type: Article

References (55)

1. Brettle RP, Wilson A, Povey S, et al. Combination therapy for HIV: The effect on inpatient activity, morbidity and mortality of a cohort of patients. Int J STD AIDS 1998;9:80-87.
2. Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy CHARTER Study. Neurology 2010;75: 2087-2096.
3. Morineau G, Vun MC, Barennes H, et al. Survival and quality of life among HIV-positive people on antiretroviral therapy in Cambodia. AIDS Patient Care STDs 2009;23:669-677.
4. Palella FJ, Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
5. Kelly JA, Kalichman SC. Behavioral research in HIV/AIDS primary and secondary prevention: Recent advances and future directions. J Consult Clin Psychol 2002;70:626-639.
6. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006;43:78-84.
7. Bangsberg DR, Deeks SG. Is average adherence to HIV antiretroviral therapy enough? J Gen Intern Med 2002;17:812-813.
8. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001;15:1181-1183.
9. Gross R, Yip B, Lo Re V, 3rd, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 2006;194:1108-1114.
10. Carrico AW, Bangsberg DR, Weiser SD, Chartier M, Dilworth SE, Riley ED. Psychiatric correlates of HAART utilization and viral load among HIV-positive impoverished persons. AIDS 2011;25:1113-1118.
11. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS 1999;13:F35-43.
12. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV + adults: Effects of cognitive dysfunction and regimen complexity. Neurology 2002;59:1944-1950.
13. Kalichman SC. Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: Implications for positive prevention interventions. Psychosom Med 2008;70:593-597.
14. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: A metaanalysis. Clin Infect Dis 2009;48:484-488.
15. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: A meta-analysis. AIDS Behav 2010;14:731-747.
16. Moore DJ, Posada C, Parikh M, et al. HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence. AIDS Behav (in press).
17. Walkup J, Akincigil A, Bilder S, Rosato NS, Crystal S. Psychiatric diagnosis and antiretroviral adherence among adolescent Medicaid beneficiaries diagnosed with human immunodeficiency virus/acquired immunodeficiency syndrome. J Nerv Ment Dis 2009;197:354-361.
18. Cournos F, McKinnon K. HIV seroprevalence among people with severe mental illness in the United States: A critical review. Clin Psychol Rev 1997;17:259-269.
19. Essock SM, Dowden S, Constantine NT, et al. Risk factors for HIV, hepatitis B, and hepatitis C among persons with severe mental illness. Psychiatr Serv 2003;54:836-841.
20. Goldberg RW. Supported medical care: A multi-faceted approach to helping HIV/hepatitis C virus co-infected adults with serious mental illness. AIDS 2005;19(Suppl 3):S215-220.
21. Rosenberg SD, Goodman LA, Osher FC, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health 2001;91:31-37.
22. Rosenberg SD, Swanson JW, Wolford GL, et al. The five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatr Serv 2003;54:827-835.
23. Klinkenberg WD, Sacks S. Mental disorders and drug abuse in persons living with HIV/AIDS. AIDS Care 2004;16(Suppl 1):S22-42.
24. Weiser SD, Wolfe WR, Bangsberg DR. The HIV epidemic among individuals with mental illness in the United States. Curr Infect Dis Rep 2004;6:404-410.
25. Gaynes BN, Pence BW, Eron JJ, Jr., Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV + patient population. Psychosom Med 2008;70:505-511.
26. Beyer JL, Taylor L, Gersing KR, Krishnan KR. Prevalence of HIV infection in a general psychiatric outpatient population. Psychosomatics 2007;48:31-37.
27. Otto-Salaj LL, Stevenson LY. Influence of psychiatric diagnoses and symptoms on HIV risk behavior in adults with serious mental illness. AIDS Read 2001;11:197-204, 206-198.
28. Sacks MH, Silberstein C, Weiler P, Perry S. HIV-related risk factors in acute psychiatric inpatients. Hosp Community Psychiatry 1990;41:449-451.
29. Walkup J, Crystal S, Sambamoorthi U. Schizophrenia and major affective disorder among Medicaid recipients with HIV/AIDS in New Jersey. Am J Public Health 1999;89:1101-1103.
30. Kemppainen JK, Levine R, Buffum M, Holzemer W, Finley P, Jensen P. Antiretroviral adherence in persons with HIV/AIDS and severe mental illness. J Nerv Ment Dis 2004;192: 395-404.
31. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Adherence to HIV antiretrovirals among persons with serious mental illness. AIDS Patient Care STDs 2003;17:179-186.
32. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care 2004;16:501-506.
33. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002;159:1927-1929.
34. Hanson M, Kramer TH, Gross W, Quintana J, Li PW, Asher R. AIDS awareness and risk behaviors among dually disordered adults. AIDS Educ Prev. Spring 1992;4:41-51.
35. Kapetanovic S, Wiegand RE, Dominguez K, et al. Associations of medically documented psychiatric diagnoses and risky health behaviors in highly active antiretroviral therapy-experienced perinatally HIV-infected youth. AIDS Patient Care STDs 2011;25:493-501.
36. Sacks M, Dermatis H, Looser-Ott S, Perry S. Seroprevalence of HIV and risk factors for AIDS in psychiatric inpatients. Hosp Community Psychiatry 1992;43:736-737.
37. Li J, McCombs JS, Stimmel GL. Costs of treating bipolar disorder in the California Medicaid (Medi-Cal) program. J Affect Disord 2002;71:131-139.
38. Scott J, Pope M. Non-adherence with mood-stabilizers: Prevalence and predictors. J Clin Psychiatry 2002;63:384-389.
39. Lee S, Rothbard AB, Noll E, Blank MB. Use of HIV and psychotropic medications among persons with serious mental illness and HIV/AIDS. Adm Policy Ment Health 2011;38:335-344.
40. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: Tthe AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committe of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000;12:255-266.
41. Amico KR, Fisher WA, Cornman DH, et al. Visual analog scale of ART adherence: Association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr 2006;42:455-459.
42. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001;134:968-977.
43. Twagirumukiza M, Kayumba PC, Kips JG, et al. Evaluation of medication adherence methods in the treatment of malaria in Rwandan infants. Malar J 2010;9:206.
44. Vriesendorp R, Cohen A, Kristanto P, et al. Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. Eur J Clin Pharmacol 2007;63:1115-1121.
45. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004;5:74-79.
46. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 2004; 36:1100-1102.
47. Levine AJ, Hinkin CH, Marion S, et al. Adherence to antiretroviral medications in HIV: Differences in data collected via self-report and electronic monitoring. Health Psychol 2006;25:329-335.
48. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 2006;10:227-245.
49. Pearson CR, Simoni JM, Hoff P, Kurth AE, Martin DP. Assessing antiretroviral adherence via electronic drug monitoring and self-report: An examination of key methodological issues. AIDS Behav 2007;11:161-173.
50. Deschamps AE, De Geest S, Vandamme AM, Bobbaers H, Peetermans WE, Van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDs 2008;22:735-743.
51. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999;29:824-830.
52. Fletcher CV, Testa MA, Brundage RC, et al. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr 2005;40:301-306.
53. Harris J, Pillinger M, Fromstein D, et al. Risk factors for medication non-adherence in an HIV infected population in the Dominican Republic. AIDS Behav 2011;15:1410-1415.
54. McCullagh P, Nelder JA. Generalized Linear Models. New York: Chapman and Hall, 1989.
55. Ford N, Nachega JB, Engel ME, Mills EJ. Directly observed antiretroviral therapy: A systematic review and meta-analysis of randomised clinical trials. Lancet 2009;374:2064-2071.